Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2001

Primary Completion Date

July 31, 2007

Conditions
Cervical Cancer
Interventions
DRUG

capecitabine

Trial Locations (10)

37203

Brookview Research, Inc., Nashville

92868

Chao Family Comprehensive Cancer Center, Orange

46202-5289

Indiana University Cancer Center, Indianapolis

52242-1009

Holden Comprehensive Cancer Center, Iowa City

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

39216-4505

University of Mississippi Medical Center, Jackson

39534-2576

Keesler Medical Center - Keesler AFB, Keesler Air Force Base

27157-1065

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

77555-0587

University of Texas Medical Branch, Galveston

N-0310

Norwegian Radium Hospital, Oslo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00016926 - Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter